Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor α-induced Apoptosis

Plasminogen activator inhibitor type 2 (PAI-2) is a serine proteinase inhibitor or serpin that is a major product of macrophages in response to endotoxin and inflammatory cytokines. We have explored the role of PAI-2 in apoptotic cell death initiated by tumor necrosis factor α (TNF). HeLa cells stably transfected with PAI-2 cDNA were protected from TNF-induced apoptosis, whereas cells transfected with antisense PAI-2 cDNA, a control gene, or the plasmid vector alone remained susceptible. The level of PAI-2 expressed by different HeLa cell clones was inversely correlated with their sensitivity to TNF. Loss of TNF sensitivity was not a result of loss of TNF receptor binding. In contrast, PAI-2 expression did not confer protection against apoptosis induced by ultraviolet or ionizing radiation. The serine proteinase urokinase-type plasminogen activator was not demonstrated to be the target of PAI-2 action. The P1-Arg amino acid residue of PAI-2 was determined to be required for protection, because cells expressing PAI-2 with an Ala in this position were not protected from TNF-mediated cell death. The results suggest that intracellular PAI-2 might be an important factor in regulating cell death in TNF-mediated inflammatory processes through inhibition of a proteinase involved in TNF-induced apoptosis.

[1]  M. Lanotte,et al.  Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis. , 1994, British Journal of Cancer.

[2]  Mark A. Murcko,et al.  Structure and mechanism of interleukin-lβ converting enzyme , 1994, Nature.

[3]  A. Copeta,et al.  Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. , 1994, Experimental cell research.

[4]  L. Tartaglia,et al.  Enhanced synthesis of tumor necrosis factor-inducible proteins, plasminogen activator inhibitor-2, manganese superoxide dismutase, and protein 28/5.6, is selectively triggered by the 55-kDa tumor necrosis factor receptor in human melanoma cells. , 1994, Journal of Biological Chemistry.

[5]  M. Hendrix,et al.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.

[6]  S. Kawabata,et al.  A Limulus intracellular coagulation inhibitor with characteristics of the serpin superfamily. Purification, characterization, and cDNA cloning. , 1994, Journal of Biological Chemistry.

[7]  Junying Yuan,et al.  Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3 , 1993, Cell.

[8]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[9]  G. Rossi,et al.  Processing of complex between urokinase and its type‐2 inhibitor on the cell surface , 1993, FEBS letters.

[10]  Mike Rothe,et al.  Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor , 1993, Cell.

[11]  W. Fiers,et al.  Effect of bcl-2 proto-oncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. , 1993, Oncogene.

[12]  T. Hennet,et al.  Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. , 1993, Cancer research.

[13]  D. Longo,et al.  Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin‐1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  D. Lomas,et al.  Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. , 1993, The Journal of biological chemistry.

[15]  W. Birchmeier,et al.  Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. , 1992, The EMBO journal.

[16]  P. Gettins,et al.  Structure and mechanism of action of serpins. , 1992, Hematology/oncology clinics of North America.

[17]  M. Krönke,et al.  Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. , 1992, The Journal of biological chemistry.

[18]  R. Black,et al.  Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme , 1992, Cell.

[19]  K. O. Elliston,et al.  A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes , 1992, Nature.

[20]  J. Dickinson,et al.  Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells. , 1992, European journal of biochemistry.

[21]  M. Gyetko,et al.  Urokinase expression in mononuclear phagocytes: cytokine‐specific modulation by interferon‐γ and tumor necrosis factor‐α , 1992, Journal of leukocyte biology.

[22]  N. Taniguchi,et al.  Phorbol ester induces manganese-superoxide dismutase in tumor necrosis factor-resistant cells. , 1991, The Journal of biological chemistry.

[23]  C. Baglioni,et al.  Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. , 1991, The Journal of biological chemistry.

[24]  L. Tartaglia,et al.  The two different receptors for tumor necrosis factor mediate distinct cellular responses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Higuchi Masahiro,et al.  Tnf-mediated cytotoxicity. importance of intracellular cgmp level for determining tnf-sensitivity☆ , 1991 .

[26]  G von Heijne,et al.  The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. , 1991, The Journal of biological chemistry.

[27]  W. Fiers Tumor necrosis factor Characterization at the molecular, cellular and in vivo level , 1991, FEBS letters.

[28]  Gwyn T. Williams Programmed cell death: Apoptosis and oncogenesis , 1991, Cell.

[29]  E. Kruithof,et al.  Plasminogen activator inhibitor-2 in patients with monocytic leukemia. , 1991, Leukemia.

[30]  C. Baglioni,et al.  Plasminogen activator inhibitor type‐2 Is a major protein induced in human fibroblasts and SK‐MEL‐109 melanoma cells by tumor necrosis factor , 1990, Journal of cellular physiology.

[31]  R. Black,et al.  Substrate specificity of the protease that processes human interleukin-1 beta. , 1990, The Journal of biological chemistry.

[32]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[33]  G. Wong,et al.  Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor , 1989, Cell.

[34]  S. T. Howard,et al.  Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. , 1989, The Journal of general virology.

[35]  A. Levinson,et al.  Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation. , 1989, The Journal of biological chemistry.

[36]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[37]  W. Fiers,et al.  Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity. , 1988, European journal of biochemistry.

[38]  L. Gooding,et al.  Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. , 1988, Journal of immunology.

[39]  E. Kruithof,et al.  Determination of intermediates, products and cleavage site in the reaction between plasminogen activator inhibitor type‐2 and urokinases , 1988, FEBS letters.

[40]  Volker Herzog,et al.  Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes , 1988, International journal of cancer.

[41]  B. Schwartz,et al.  Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. , 1988, Blood.

[42]  M. Clark,et al.  Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Carrell,et al.  Genetic engineering and the serpins. , 1988, BioEssays : news and reviews in molecular, cellular and developmental biology.

[44]  R. Medcalf,et al.  Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells , 1987, Molecular and cellular biology.

[45]  B. Binder,et al.  Proliferation of a human epidermal tumor cell line stimulated by urokinase , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  V. Ruggiero,et al.  Protection from tumor necrosis factor cytotoxicity by protease inhibitors. , 1987, Cellular Immunology.

[47]  D. Belin,et al.  Amiloride selectively inhibits the urokinase‐type plasminogen activator , 1987, FEBS letters.

[48]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[49]  B. Aggarwal,et al.  Effects of growth factors on the antiproliferative activity of tumor necrosis factors. , 1987, Cancer research.

[50]  B. Aggarwal,et al.  Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. , 1985, Science.

[51]  D. Wallach Preparations of lymphotoxin induce resistance to their own cytotoxic effect. , 1984, Journal of immunology.

[52]  R. Stephens,et al.  Novel properties of human monocyte plasminogen activator. , 1984, European journal of biochemistry.

[53]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[54]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[55]  A. Wyllie Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.

[56]  E. Shaw,et al.  The susceptibility of urokinase to affinity labeling by peptides of arginine chloromethyl ketone. , 1979, Biochimica et biophysica acta.

[57]  T. Chen,et al.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. , 1977, Experimental cell research.

[58]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[59]  T. Kawano,et al.  Partial purification and properties of urokinase inhibitor from human placenta. , 1970, Journal of biochemistry.

[60]  P. Quax,et al.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. , 1994, The American journal of pathology.

[61]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[62]  D. Belin,et al.  Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system. , 1992, Current topics in microbiology and immunology.

[63]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[64]  W. V. Shaw [57] Chloramphenicol acetyltransferase from chloramphenicol-resistant bacteria , 1975 .